Anna Herring
Physician Assistant · Spring Hill, TNNPI 1861420101
Payments from drug & device makers
Across 410 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Amgen$706
- Lilly USA, LLC$496
- Pfizer$409
- Astellas Pharma US Inc$336
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,12798%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,096 |
| AbbVie(2 entities) | 65 | $1,078 |
| Amgen | 43 | $706 |
| Lilly USA, LLC | 32 | $496 |
| Pfizer | 23 | $409 |
| Astellas Pharma US Inc | 14 | $336 |
| Johnson & Johnson | 19 | $329 |
| Abbott | 14 | $298 |
| AstraZeneca | 18 | $264 |
| Boehringer Ingelheim | 14 | $234 |
| GSK | 13 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $209 |
| Boston Scientific | 8 | $183 |
| Esperion Therapeutics, Inc. | 10 | $176 |
| Bayer | 7 | $156 |
| Lundbeck LLC | 7 | $150 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Exact Sciences | 3 | $74 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| IBSA Pharma Inc. | 1 | $54 |
| Shield Therapeutics Inc | 3 | $54 |
| Antares Pharma, Inc. | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Eisai Inc. | 2 | $46 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| Acella Pharmaceuticals, LLC | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Harmony Biosciences LLC | 1 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Corium, LLC | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Merck | 1 | $13 |
How this compares
$7,255 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 143 | $167,324 |
| JardianceEmpagliflozin | 37 | $55,505 |
| OzempicSemaglutide | 39 | $42,941 |
| ProliaDenosumab | 15 | $25,816 |
| JanuviaSitagliptin Phosphate | 15 | $23,206 |
| TrulicityDulaglutide | 13 | $21,640 |
| FarxigaDapagliflozin Propanediol | 25 | $20,601 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $20,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $18,473 |
| TradjentaLinagliptin | 11 | $15,115 |
| MyrbetriqMirabegron | 16 | $12,970 |
| Repatha SureclickEvolocumab | 15 | $10,947 |
| EliquisApixaban | 18 | $10,402 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,169 |
| KerendiaFinerenone | 11 | $8,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $496 | $188,964156 claims |
| Boehringer IngelheimJardiance, Tradjenta | $234 | $70,62048 claims |
| Novo NordiskOzempic | $1,096 | $42,94139 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $232 | $28,64246 claims |
| AmgenProlia | $706 | $25,81615 claims |
| MerckJanuvia | $13 | $23,20615 claims |
| AstraZenecaFarxiga | $264 | $20,60125 claims |
| PfizerEliquis, Paxlovid | $409 | $14,42630 claims |
| Astellas Pharma US IncMyrbetriq | $336 | $12,97016 claims |
| AbbVieLinzess, Synthroid | $1,078 | $10,95166 claims |
| BayerKerendia | $156 | $8,29111 claims |
| Eisai Inc.Dayvigo | $46 | $3,74512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Spring Hill
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- Katherine RunyanKnoxville$156K
- John KramerNashville$125K
- Robert LaughertyAlcoa$122K
- Elisabeth BennettNashville$109K
- Whitney GatewoodMemphis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.